(19)
(11) EP 0 815 872 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
10.12.2003 Bulletin 2003/50

(43) Date of publication A2:
07.01.1998 Bulletin 1998/02

(21) Application number: 97201981.4

(22) Date of filing: 17.01.1994
(51) International Patent Classification (IPC)7: A61K 47/48
(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 15.01.1993 GB 9300686

(62) Application number of the earlier application in accordance with Art. 76 EPC:
94904270.9 / 0679094

(71) Applicant: Cancer Therapeutics Limited
Ealing, London W5 3QR (GB)

(72) Inventors:
  • Epenetos, Agamemnon Antoniou
    Ealing, London W5 3QR (GB)
  • Spooner, Robert Anthony, ICRF Oncology Group
    Du Cane Road, London W12 0HS (GB)
  • Deonarain, Mahendra, ICRF Oncology Group
    Du Cane Road, London W12 0HS (GB)

(74) Representative: Bassett, Richard Simon et al
Eric Potter Clarkson, Park View House, 58 The Ropewalk
Nottingham NG1 5DD
Nottingham NG1 5DD (GB)

   


(54) Compounds for targeting


(57) A compound comprising a target cell-specific portion and a directly or indirectly cytotoxic portion, characterised in that the target cell-specific portion recognises the target cell with high avidity. The cytotoxic portions of the compound may be a subunit of an oligomer, may contain a binding site for a small molecule, may be streptavidin, may be a dimeric ribonuclease or may be DNAse-I. The target cell-specific portion may comprise two or more binding sites for the target cell, may be an antibody or fragment thereof, or may be a ScFv. A compound suitable for cell agglutination, particularly haemagglutination. A compound comprising a mediator portion and a directly or indirectly cytotoxic portion wherein the mediator portion recognises a target cell-specific molecule and provides a means of indirect targeting.















Search report